Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer’s disease pathology
Year: 2026
Type: article
Study design: Observational Study
Abstract: Plasma biomarkers for Alzheimer’s disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ 42 ) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ 42 /Aβ 40 and p-tau181/Aβ 42 ) for identifying AD pathology (Aβ-PET visual read) across a memory clinic ( n = 129), a primary care ( n = 220) and a research cohort ( n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83–91%) and p-tau217/Aβ 42 (83–92%) had comparable accuracies to CSF (88–90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90–97%) remained comparable to CSF (91%) in the clinical cohorts (all P adj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ 42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.
Source: Nature Aging
Authors: Noëlle Warmenhoven, Alexa Pichet Binette, Lyduine E. Collij, Shorena Janelidze, Niklas Mattsson-Carlgren, Pontus Tideman, Ruben Smith, Olof Strandberg, Nicholas J. Ashton, Henrik Zetterberg, Alzheimer’s Disease Neuroimaging Initiative, Michael Weiner, Erik Stomrud, Gemma Salvadó, Oskar Hansson, Sebastian Palmqvist
Institutions: Lund University, Institut Universitaire de Gériatrie de Montréal, Université de Montréal, Amsterdam Neuroscience, Amsterdam UMC Location Vrije Universiteit Amsterdam, Skåne University Hospital, Sahlgrenska University Hospital, Banner Sun Health Research Institute, Banner Alzheimer’s Institute, University of Gothenburg, University of Wisconsin–Madison, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London, University of California, San Francisco, Northern California Institute for Research and Education, Pasqual Maragall Foundation, Barcelonaβeta Brain Research Center, Hospital del Mar Research Institute
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $12,690
Funders: U.S. Department of Defense, Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Roche, Biogen, University of Southern California, Meso Scale Diagnostics, Alzheimer's Disease Neuroimaging Initiative, Cure Alzheimer's Fund, BioClinica, Novartis Pharmaceuticals Corporation, Northern California Institute for Research and Education, Australian Government, GHR Foundation, Lunds Universitet, Eisai, Vetenskapsrådet, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skånes universitetssjukhus, Servier, H. Lundbeck A/S, IXICO, Stiftelsen Bundy Academy, National Institutes of Health, Genentech, Parkinsonfonden, Canadian Institutes of Health Research, Janssen Alzheimer Immunotherapy Research And Development
Awards: G1012222616, G1120803110, G1298807586, G1304444302, G1469549138, G1554142629, G1593117279, G1650819308, G1880935189, G2043619954, G2100670906, G2152643862, G2189010064, G2340207221, G2423387114, G2465228561, G2471646051, G2522063444, G2835601961, G29951154, G3131374986, G3277900835, G3553156159, G3678370191, G3710456697, G3752451908, G3870774570, Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease, G3908963977, G3966393351, G4038479886, G4196769506, G43180419, G4501223628, G4800177743, G4977467247, G5184609404, G5207404921, G5209990037, G528601746, G5365730499, G5524304478, G5585422332, G5654639750, G5740349702, G6011188351, G613619302, G6173816828, G6210868510, G6365185080, G6371410416, G6412110892, G6447063303, G6719828067, Prospective validation of high-performing blood biomarkers and digital cognitive tests in both specialist memory clinic and general primary care settings, G6792506723, G681300203, G6899163935, G7021656695, G7153071485, G72415811, G7298697282, Development of biomarkers in Alzheimer’s disease: improvement of early and accurate diagnosis and increased understanding of disease mechanisms that facilitates drug development, A precision medicine approach for the diagnosis and prognosis of preclinical Alzheimer´s disease with implications for clinical trials, G764699806, G7799614282, G781725486, G8019856391, G822442210, G8228018387, G8281378126, G839208290, G8598463824, G8852128998, G8895907669, G8897063270, G8917015137, G8957659042, G9000122335, G9000360447
OpenAlex ID: W7235972385
